Cargando…

Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy

The present study aimed to evaluate changes in the expression patterns at the gene and protein levels associated with drug resistance. The study group included 48 women who had a histopathologically confirmed diagnosis of stage I-IV ovarian cancer, they were divided into two subgroups (groups A and...

Descripción completa

Detalles Bibliográficos
Autores principales: Opławski, Marcin, Średnicka, Agata, Niewiadomska, Ewa, Boroń, Dariusz, Januszyk, Piotr, Grabarek, Beniamin Oskar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389532/
https://www.ncbi.nlm.nih.gov/pubmed/35992817
http://dx.doi.org/10.3389/fonc.2022.954008
_version_ 1784770481948196864
author Opławski, Marcin
Średnicka, Agata
Niewiadomska, Ewa
Boroń, Dariusz
Januszyk, Piotr
Grabarek, Beniamin Oskar
author_facet Opławski, Marcin
Średnicka, Agata
Niewiadomska, Ewa
Boroń, Dariusz
Januszyk, Piotr
Grabarek, Beniamin Oskar
author_sort Opławski, Marcin
collection PubMed
description The present study aimed to evaluate changes in the expression patterns at the gene and protein levels associated with drug resistance. The study group included 48 women who had a histopathologically confirmed diagnosis of stage I-IV ovarian cancer, they were divided into two subgroups (groups A and B). In group A, there were 36 patients in whom surgical treatment was supplemented with first-line chemotherapy according to current standards. Within this patient group, 5 had stage I (14%), 5 had stage II (14%), 25 had stage III (69%), and 1 had stage IV ovarian cancer (3%). Drug resistance was found after the third cycle of chemotherapy in 17 patients (71%) and after the sixth cycle in 7 patients (29%). Group B included 12 women with type I ovarian cancer, including 11 with stage I and 1 patient with stage IV ovarian cancer. The oncological treatment required only surgery. The control group (C) included 50 women in whom the uterus and adnexa were surgically removed for non-oncological reasons. Significantly higher levels of carcinoma antigen 125 CA-125 and human epididymis protein 4 HE4 were observed in group A and in menopausal women. Moreover, drug resistance was associated with significantly higher levels of CA-125 (p < 0.05). The genes UBA2, GLO1, STATH, and TUFT1 were differentiated in test samples from control samples. Moreover, drug resistance was associated with significantly higher expression of GLO1. The results of these assessments indicated the strong link between UBA2 and hsa-miR-133a-3p and hsa-miR-133b; GLO1 and hsa-miR-561-5p; STATH and hsa-miR-137-3p and hsa-miR-580-3p; and TUFT1 and hsa-miR-1233-3p and hsa-miR-2052. Correlation analysis showed a significant correlation between CA-125 and HE4 levels. Moreover, a significant correlation between TUFT1 mRNA and UBA2, GLO1, STATH (negative correlation), and TUFT1 in relation to CA-125 and HE4 (p < 0.05) was noted in all patients. In view of the lack of screening tests for ovarian cancer, the occurrence of the described correlation may be inscribed as an attempt to establish an assay that meets the criteria of a screening test and thus increase the early diagnosis of ovarian cancer.
format Online
Article
Text
id pubmed-9389532
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93895322022-08-20 Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy Opławski, Marcin Średnicka, Agata Niewiadomska, Ewa Boroń, Dariusz Januszyk, Piotr Grabarek, Beniamin Oskar Front Oncol Oncology The present study aimed to evaluate changes in the expression patterns at the gene and protein levels associated with drug resistance. The study group included 48 women who had a histopathologically confirmed diagnosis of stage I-IV ovarian cancer, they were divided into two subgroups (groups A and B). In group A, there were 36 patients in whom surgical treatment was supplemented with first-line chemotherapy according to current standards. Within this patient group, 5 had stage I (14%), 5 had stage II (14%), 25 had stage III (69%), and 1 had stage IV ovarian cancer (3%). Drug resistance was found after the third cycle of chemotherapy in 17 patients (71%) and after the sixth cycle in 7 patients (29%). Group B included 12 women with type I ovarian cancer, including 11 with stage I and 1 patient with stage IV ovarian cancer. The oncological treatment required only surgery. The control group (C) included 50 women in whom the uterus and adnexa were surgically removed for non-oncological reasons. Significantly higher levels of carcinoma antigen 125 CA-125 and human epididymis protein 4 HE4 were observed in group A and in menopausal women. Moreover, drug resistance was associated with significantly higher levels of CA-125 (p < 0.05). The genes UBA2, GLO1, STATH, and TUFT1 were differentiated in test samples from control samples. Moreover, drug resistance was associated with significantly higher expression of GLO1. The results of these assessments indicated the strong link between UBA2 and hsa-miR-133a-3p and hsa-miR-133b; GLO1 and hsa-miR-561-5p; STATH and hsa-miR-137-3p and hsa-miR-580-3p; and TUFT1 and hsa-miR-1233-3p and hsa-miR-2052. Correlation analysis showed a significant correlation between CA-125 and HE4 levels. Moreover, a significant correlation between TUFT1 mRNA and UBA2, GLO1, STATH (negative correlation), and TUFT1 in relation to CA-125 and HE4 (p < 0.05) was noted in all patients. In view of the lack of screening tests for ovarian cancer, the occurrence of the described correlation may be inscribed as an attempt to establish an assay that meets the criteria of a screening test and thus increase the early diagnosis of ovarian cancer. Frontiers Media S.A. 2022-08-05 /pmc/articles/PMC9389532/ /pubmed/35992817 http://dx.doi.org/10.3389/fonc.2022.954008 Text en Copyright © 2022 Opławski, Średnicka, Niewiadomska, Boroń, Januszyk and Grabarek https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Opławski, Marcin
Średnicka, Agata
Niewiadomska, Ewa
Boroń, Dariusz
Januszyk, Piotr
Grabarek, Beniamin Oskar
Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy
title Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy
title_full Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy
title_fullStr Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy
title_full_unstemmed Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy
title_short Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy
title_sort clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389532/
https://www.ncbi.nlm.nih.gov/pubmed/35992817
http://dx.doi.org/10.3389/fonc.2022.954008
work_keys_str_mv AT opławskimarcin clinicalandmolecularevaluationofpatientswithovariancancerinthecontextofdrugresistancetochemotherapy
AT srednickaagata clinicalandmolecularevaluationofpatientswithovariancancerinthecontextofdrugresistancetochemotherapy
AT niewiadomskaewa clinicalandmolecularevaluationofpatientswithovariancancerinthecontextofdrugresistancetochemotherapy
AT borondariusz clinicalandmolecularevaluationofpatientswithovariancancerinthecontextofdrugresistancetochemotherapy
AT januszykpiotr clinicalandmolecularevaluationofpatientswithovariancancerinthecontextofdrugresistancetochemotherapy
AT grabarekbeniaminoskar clinicalandmolecularevaluationofpatientswithovariancancerinthecontextofdrugresistancetochemotherapy